A 52-percentage-point gap in 24-month overall survival is not a marginal improvement — it is the kind of signal that rewrites treatment algorithms. The ROADS phase 3 trial, enrolling 230 patients across 32 U.S. centers, showed that intraoperative placement of cesium-131 collagen tiles (GammaTile) produced a 24-month overall survival rate of 61.7% versus 35.7% for surgery followed by stereotactic radiotherapy, with a hazard ratio of 0.59. That survival advantage, combined with a 12-month surgical bed recurrence rate of just 1.0% against 11.9% for the standard-of-care arm, gives this trial a rare combination: a clean co-primary endpoint win and a secondary survival benefit that most neuro-oncologyoncology trials never reach.
The design insight embedded in GammaTile is straightforward but has taken years to prove rigorously: the gap between resection and adjuvant SRT — typically three to eight weeks — is not a neutral waiting period. Residual tumor cells proliferate in exactly that window, and roughly 20% of patients never complete prescribed post-operative radiation at all. By delivering radiation at the moment of surgery, TBRT collapses the entire cranial management timeline to a median of one day versus 30 days for SRT. The trial did not just close that gap conceptually; it demonstrated the biological consequence of closing it, with a greater than 50% reduction in risk of recurrence or death (HR 0.48, p=0.002).
What makes these results particularly credible is the toxicity profile — or rather, the absence of a differentiating one. Radiation necrosis, leptomeningeal disease, adverse events, and quality-of-life scores were statistically comparable between arms. That symmetry matters enormously for guideline bodies and tumor boards. A device that buys survival at the cost of meaningful neurotoxicity faces an entirely different adoption fight than one that does not. ROADS eliminates that objection, which is the central objection that has slowed intraoperative brachytherapy uptake in brain tumors for two decades.
GammaTile already carries FDA clearance, so the regulatory pathway is not the constraint here — payer coverage policy and neurosurgical center adoption are. The number to watch is whether NCCN updates its brain metastases guidelines to include TBRT as a Category 1 recommendation, because that designation is what converts a compelling phase 3 result into a reimbursement-defensible standard of care at community cancer centers beyond the 32 trial sites.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
